Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Immunogen Inc (NQ: IMGN ) N/A UNCHANGED Last Price Updated: 4:00 PM EST, Feb 9, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Immunogen Inc < Previous 1 2 3 4 5 6 7 8 9 Next > 3 Unstoppable Mega-Cap Stocks That Every Investor Should Own in 2024 March 09, 2024 Dive into the world of three unstoppable mega-cap stocks leading the charge amidst the bullishness in the market. Via InvestorPlace Amicus Therapeutics Stock Sees Improved Relative Strength Rating February 09, 2024 In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 64 to 78 on Friday. Via Investor's Business Daily 3 Strong Buy Biotech Stocks to Add to Your February Must-Watch List February 06, 2024 These biotech stocks offer investors huge potential in the future. Investors may want to consider these equities to enter the industry. Via InvestorPlace 7 Russell 2000 Stocks to Buy for the Next Bull Run: February 2024 February 06, 2024 Unveil these standout Russell 2000 stocks, meticulously picked to harness the potential of the evolving market landscape in the 2024 surge. Via InvestorPlace Madrigal Pharmaceuticals Stock Shows Rising Relative Strength February 06, 2024 A Relative Strength Rating upgrade for Madrigal Pharmaceuticals shows improving technical performance. Via Investor's Business Daily AbbVie Lifts Long-Term Outlook For New Immunology Drugs, Even As Q4 Revenue and Profit Fall February 02, 2024 AbbVie reports Q4 earnings with adjusted EPS at $2.79, beating consensus. Sees FY 2024 EPS of $11.05-$11.25. Raises 2027 outlook for key products. Via Benzinga AbbVie's Transformational 2023, Analyst Anticipates Growth in 2024 Amid Competitive Pressures January 29, 2024 AbbVie's growth outlook in 2024 as William Blair upgrades, highlighting strong performance in Humira erosion management, strategic acquisitions, and a 3.8% dividend yield. Via Benzinga Investors Take Note as Corbus Pharma Releases Data for ADC Tumor Candidate January 29, 2024 --News Direct-- Via News Direct ABBV: This Top Biotech Just Went On A Buying Spree January 25, 2024 AbbVie stock is a buy following its recent merger & acquisition activity (Immunogen and Cerevel). Via Talk Markets Axsome Therapeutics Stock Showing Leadership, Earns 91 RS Rating January 23, 2024 Axsome Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating. Via Investor's Business Daily 7 Dividend Aristocrats That Will Pay You for Years to Come January 22, 2024 If you're looking for a consistent income, consider some of these top Dividend Aristocrats to buy and hold in 2024. Via InvestorPlace Ultragenyx Pharm Stock Earns IBD Stock Upgrade With RS Rating Jump To 83 January 18, 2024 On Thursday, Ultragenyx Pharm stock just cleared that 80 or higher RS Rating benchmark with an upgrade from 75 to 83. Via Investor's Business Daily Cassava Sciences Stock Continues Showing Rising Relative Strength January 16, 2024 Cassava Sciences sees its Relative Strength Rating move into the elite 90-plus level. Via Investor's Business Daily Cramer Says This Major Healthcare Stock Is 'Ridiculously Cheap And Doing So Many Great Things' January 08, 2024 On CNBC’s "Mad Money Lightning Round," Jim Cramer said he likes Realty Income (NYSE: O) and recommends staying with it. "It’s a very steady story," he noted. Via Benzinga Is AbbVie Stock a Buy Now? January 07, 2024 The company is grappling with losing Humira's patent protection in 2023. Via The Motley Fool Topics Intellectual Property Exposures Intellectual Property Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024 January 05, 2024 Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain. Via Investor's Business Daily 3 Biotech Stocks Set for Breakthroughs in 2024 January 02, 2024 With groundbreaking advancements in new medicine and science, 2024 holds a promising future for these biotech stocks. Via InvestorPlace 10 Health Care Stocks Whale Activity In Today's Session January 02, 2024 Via Benzinga Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024 December 29, 2023 According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023. Via Benzinga AbbVie's Recent ImmunoGen Acquisition Looks Brilliant: Here's Why December 26, 2023 The acquisition fills an immediate need with some extras to boot. Via The Motley Fool 3 Stocks at the Forefront of Medical Innovation December 25, 2023 Boring businesses and industries typically show new faces when technology comes around; today, these biotech stocks are leading the way. Via InvestorPlace Tarsus Pharmaceuticals Stock Scores Relative Strength Rating Upgrade December 21, 2023 On Thursday, Tarsus Pharmaceuticals stock reached a key technical milestone, seeing its Relative Strength Rating jump to 91 from 84. Via Investor's Business Daily The 7 Most Undervalued Growth Stocks to Buy in December December 13, 2023 Buy these distressed names now and ride their share prices higher over the coming year as they stage a comeback. Via InvestorPlace Cassava Sciences Stock Shows Rising Relative Strength Following 3 Up Days December 13, 2023 Cassava Sciences sees its Relative Strength Rating reach the 80-plus level. Via Investor's Business Daily AbbVie Just Followed Pfizer's Big Move. Here's What It Means For Investors December 12, 2023 It's making a major acquisition to beef up a key area of its pipeline. Via The Motley Fool Bristol Myers Squibb Further Diversifies Oncology Portfolio With Mega $8.4B Deal December 12, 2023 SystImmune and Bristol Myers Squibb & Co (NYSE: BMY) Via Benzinga 10 Health Care Stocks With Whale Alerts In Today's Session December 11, 2023 Via Benzinga The 3 Best Cheap Stocks to Buy in December December 10, 2023 Investors wanting to buy low and sell high should consider a position in one of these great companies whose shares have pulled back lately. Via InvestorPlace AbbVie Just Announced 2 Big Acquisitions: Is This Dividend King a No-Brainer Buy Right Now? December 10, 2023 The big drugmaker went on a holiday shopping spree. Via The Motley Fool Market Movers: Why Big Players Are Investing Millions in These 3 Stocks December 08, 2023 In investing, certain stocks catch the discerning eye of big players, drawing in substantial investments. Via InvestorPlace < Previous 1 2 3 4 5 6 7 8 9 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
